Emerging Growth Equities, Ltd. Initiates Coverage of eResearchTechnology, Inc. (Nasdaq: ERES) with a BUY Rating

Emerging Growth Equities, Ltd. Initiates Coverage of
eResearchTechnology, Inc. (Nasdaq: ERES) with a BUY Rating 


KING OF PRUSSIA, Pa., July 20  /PRNewswire/ -- Emerging Growth Equities, Ltd.
initiates coverage of eResearchTechnology, Inc. (NASDAQ:ERES) with a BUY rating
and a 12-month price target of $37.50.  eResearch is the leader in ECG
(electrocardiograph) analysis in support of clinical trials evaluating the
safety of pharmaceutical and biologic product candidates.

Emerging Growth Equities, Ltd. is a specialty brokerage and investment banking
firm providing high-quality distribution, research and trade execution for
institutional and retail clients.  Emerging Growth Equities, Ltd. specializes
in fulfilling the capital requirements of well-managed emerging growth
companies.  Emerging Growth Equities, Ltd. maintains a market in ERES with the
market maker ID EGRO.

For a full text of the report please call 888-293-1800.

This publication is neither an offer to sell nor a solicitation to buy any
securities mentioned herein.  The information contained herein is based on data
obtained from recognized sources that are believed to be reliable. Emerging
Growth Equities, Ltd. has not independently verified the facts, assumptions and
estimates contained in this report.  Accordingly, no representation or
warranty, expressed or implied, is made as to, and no reliance should be placed
on, the fairness, accuracy, completeness or correctness of the information and
opinions contained in this report.  The information contained in this report is
not and does not purport to be a complete analysis of every material fact
respecting any company, industry, or security.

Most of the companies Emerging Growth Equities, Ltd. follows are emerging and
mid-sized growth companies whose securities typically involve a higher degree
of risk and more volatility than the securities of more established companies. 
For these and other reasons, the investments discussed or recommended in this
report may be unsuitable for investors depending on their specific investment
objectives and financial position.  Transactions in securities mentioned herein
may be effected only in those states where such securities are qualified for
sale.

Any statements nonfactual in nature herein constitute only current opinions or
estimates, represent only the current judgment of the author(s), and are
subject to change without notice.  This report contains forward- looking
statements, which involve risks and uncertainties.  Actual results may differ
significantly from the results described in the forward-looking statements. 
Emerging Growth Equities, Ltd. (or one of its affiliates) or their partners,
officers, directors, analysts, employees or customers may have an interest in
the securities mentioned herein and may make purchases or sales as principal or
agent of these securities, or their derivatives, while this report is in
circulation.  A partner, employee, analyst, officer, or director of Emerging
Growth Equities, Ltd. (or one of its affiliates) may serve as a director or
consultant for any company mentioned herein.  Emerging Growth Equities, Ltd.
(or one of its affiliates) may from time to time perform investment banking
services for, or solicit investment banking business or other business from,
any company mentioned herein.  Additional information on the securities
discussed herein is available on request.

Emerging Growth Equities, Ltd. is a member of the National Association of
Securities Dealers, CRD number 47040. 

DATASOURCE: Emerging Growth Equities, Ltd.



CONTACT:  Raymond A. Myers, CFA, Healthcare Analyst, Emerging Growth

Equities, Ltd., [phone] or [phone]

Copyright